Search PubMed⌕ Search

Biomedical subjects

A Duran

Publications and source records attributed to A Duran.

63 records · Page 4Linked to original sources

Solubilization and partial purification of yeast chitin synthetase. Confirmation of the zymogenic nature of the enzyme.

Chitin synthetase was solubilized with digitonin from a particulate yeast fraction. The solubilized enzyme, which did not sediment at 200,000 X g and emerged after the void volume in a Sepharose 6B column, was active only after treatment with a protease. This confirms that chitin synthetase exists in the plasma membrane as a zymogen and that initiation of the chitin septum occurs by localized activation of the enzyme. By differential extraction with sodium cholate and digitonin, followed by chromatography on Sepharose 6B, a 20-fold purification of the enzyme was achieved with respect to the crude particles. The purified enzyme showed a requirement for a phospholipid; phosphatidylserine and lysophosphatidylserine were the best activators. Unsaturated fatty acids strongly inhibited synthetase activity, whereas their saturated counterparts were inert. The solubilized enzyme catalyzed the formation of insoluble chitin in the absence of added primer. The synthetic polysaccharide was examined by electron microscopy and found to consist of lozenge-shaped particles about 60 nm long and 10 nm wide.

Chitin Synthase↗

[The technic of arterial blood-specimen collection in cattle].

A simple method of collecting arterial blood in cattle by puncture of the arteria iliaca externa per rectum is described. Individual collections do not induce any local reaction nor do they impair the overall condition and milk yield of the animals.

Animals↗

Clinical and biological characteristics of myelodysplastic syndromes with nulisomy Y by fish.

BACKGROUND AND OBJECTIVE: In the present study we analyzed the incidence of nulisomy Y by fluorescence in situ hybridization in a group of 24 males diagnosed with myelodysplastic syndromes (MDS). We explored the relationship between this chromosome abnormality and other clinical and biological disease characteristics. METHODS: Loss of chromosome Y was present in 7 out of the 24 males analyzed (29%); the number of cells carrying this chromosome aberration ranged between 19% and 90%. From the clinicobiological point of view, the group of patients with nulisomy Y showed a higher incidence of RA and RAS FAB subtypes (p = 0.04), a lower WBC count (p = 0.04), a lower proportion of blast cells both in PB (p = 0.009) and BM (p = 0.06) associated with a decreased myeloid/erythroid ratio (p = 0.01). RESULTS: No clear association was detected between loss of chromosome Y and other numerical chromosome abnormalities involving chromosomes 7 and 8. In contrast, 2 out of the 7 cases with loss of chromosome Y also displayed monosomy 1 by FISH. However, the use of appropriate dual stainings showed that these two abnormalities were present in different cell populations (that is, they never coexisted in the same cell population), which supports the notion of the existence of clonal heterogeneity in MDS patients. INTERPRETATION AND CONCLUSIONS: From the prognostic point of view, MDS patients with loss of chromosome Y displayed a higher survival rate, although these differences did not reach statistical significance.

Adult↗